SOUTH SAN FRANCISCO, Calif.,
Sept. 20, 2017 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing
proprietary therapeutics for the treatment of select chronic
diseases utilizing its ProNeura™ long-term, continuous drug
delivery technology, announced today that Titan President and CEO
Sunil Bhonsle will present at the
Cantor Fitzgerald Global Healthcare Conference on Wednesday, Sept. 27 at 9:45 a.m. EDT at the Intercontinental New York
Barclay Hotel.
Mr. Bhonsle will review the company's ProNeura-based pipeline of
clinical and early-stage product candidates, as well as provide a
market update on Probuphine for the maintenance treatment of opioid
dependence. The presentation will be available as a live and
archived webcast on the Events page on Titan's website.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is developing
proprietary therapeutics primarily for the treatment of serious
medical disorders. The company's lead product is Probuphine®, a
novel and long-acting formulation of buprenorphine and the first
and only commercialized treatment of opioid dependence approved by
the U.S. Food and Drug Administration to provide continuous,
around-the-clock blood levels of buprenorphine for six months
following a single procedure. Probuphine employs Titan's
proprietary drug delivery system ProNeura™, which is capable of
delivering sustained, consistent levels of medication for three
months or longer. Titan has granted commercial rights in the U.S.
and Canada for Probuphine to
Braeburn Pharmaceuticals. The ProNeura technology has the potential
to be used in developing products for treating other chronic
conditions such as Parkinson's disease and hypothyroidism, where
maintaining consistent, around-the-clock blood levels of medication
may benefit the patient and improve medical outcomes. For more
information about Titan, please visit www.titanpharm.com.
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACT:
Titan Pharmaceuticals, Inc.:
Sunil Bhonsle, President
(650) 244-4990
Investors:
Stephen Kilmer
(650) 989-2215
skilmer@titanpharm.com
Media:
Susan Thomas
(650) 989-2216
sthomas@titanpharm.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-to-present-at-cantor-fitzgerald-global-healthcare-conference-300523229.html
SOURCE Titan Pharmaceuticals, Inc.